Thus, interfering with Furin activity-mediated Ca2+ mobilization and Orai and TRPC6 activation represent a potential strategy controlling malignant phenotype and resistance to therapy in triple negative breast cancer cells. This evidence concerns the gene FURIN and triple-negative breast carcinoma.